Refining the Impact of Genetic Evidence on Clinical Success

Overview

Journal Nature

Specialty Science

Date 2024 Apr 17

PMID 38632401

Authors

Eric Vallabh Minikel

Jeffery L Painter

Coco Chengliang Dong

Matthew R Nelson

Affiliations

Soon will be listed here.

Abstract

The cost of drug discovery and development is driven primarily by failure, with only about 10% of clinical programmes eventually receiving approval. We previously estimated that human genetic evidence doubles the success rate from clinical development to approval. In this study we leverage the growth in genetic evidence over the past decade to better understand the characteristics that distinguish clinical success and failure. We estimate the probability of success for drug mechanisms with genetic support is 2.6 times greater than those without. This relative success varies among therapy areas and development phases, and improves with increasing confidence in the causal gene, but is largely unaffected by genetic effect size, minor allele frequency or year of discovery. These results indicate we are far from reaching peak genetic insights to aid the discovery of targets for more effective drugs.

Citing Articles

Integration of functional genomics and statistical fine-mapping systematically characterizes adult-onset and childhood-onset asthma genetic associations.

Zhong X, Mitchell R, Billstrand C, Thompson E, Sakabe N, Aneas I medRxiv. 2025; .

PMID: 40034789 PMC: 11875274. DOI: 10.1101/2025.02.11.25322088.

Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets.

Chin D, Hernandez-Beeftink T, Donoghue L, Guillen-Guio B, Guillen-Uio B, Leavy O medRxiv. 2025; .

PMID: 39974050 PMC: 11838657. DOI: 10.1101/2025.01.30.25321017.

Drug-target Mendelian randomisation applied to metabolic dysfunction-associated steatotic liver disease: opportunities and challenges.

Luo S, Zheng M, Wong V, Au Yeung S eGastroenterology. 2025; 2(4):e100114.

PMID: 39944268 PMC: 11770435. DOI: 10.1136/egastro-2024-100114.

Specificity, length, and luck: How genes are prioritized by rare and common variant association studies.

Spence J, Mostafavi H, Ota M, Milind N, Gjorgjieva T, Smith C bioRxiv. 2025; .

PMID: 39935885 PMC: 11812597. DOI: 10.1101/2024.12.12.628073.

UK Biobank-A Unique Resource for Discovery and Translation Research on Genetics and Neurologic Disease.

Taylor H, Lewins M, Foody M, Gray O, Besevic J, Conroy M Neurol Genet. 2025; 11(1):e200226.

PMID: 39911793 PMC: 11796045. DOI: 10.1212/NXG.0000000000200226.

References

DiMasi J, Grabowski H, Hansen R . Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016; 47:20-33. DOI: 10.1016/j.jhealeco.2016.01.012. View

Hay M, Thomas D, Craighead J, Economides C, Rosenthal J . Clinical development success rates for investigational drugs. Nat Biotechnol. 2014; 32(1):40-51. DOI: 10.1038/nbt.2786. View

Wong C, Siah K, Lo A . Estimation of clinical trial success rates and related parameters. Biostatistics. 2018; 20(2):273-286. PMC: 6409418. DOI: 10.1093/biostatistics/kxx069. View

Nelson M, Tipney H, Painter J, Shen J, Nicoletti P, Shen Y . The support of human genetic evidence for approved drug indications. Nat Genet. 2015; 47(8):856-60. DOI: 10.1038/ng.3314. View

Diogo D, Tian C, Franklin C, Alanne-Kinnunen M, March M, Spencer C . Phenome-wide association studies across large population cohorts support drug target validation. Nat Commun. 2018; 9(1):4285. PMC: 6191429. DOI: 10.1038/s41467-018-06540-3. View

Plenge R, Scolnick E, Altshuler D . Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013; 12(8):581-94. DOI: 10.1038/nrd4051. View

Musunuru K, Kathiresan S . Genetics of Common, Complex Coronary Artery Disease. Cell. 2019; 177(1):132-145. DOI: 10.1016/j.cell.2019.02.015. View

Trajanoska K, Bherer C, Taliun D, Zhou S, Richards J, Mooser V . From target discovery to clinical drug development with human genetics. Nature. 2023; 620(7975):737-745. DOI: 10.1038/s41586-023-06388-8. View

Burgess S, Mason A, Grant A, Slob E, Gkatzionis A, Zuber V . Using genetic association data to guide drug discovery and development: Review of methods and applications. Am J Hum Genet. 2023; 110(2):195-214. PMC: 9943784. DOI: 10.1016/j.ajhg.2022.12.017. View

10.

Carss K, Deaton A, Del Rio-Espinola A, Diogo D, Fielden M, Kulkarni D . Using human genetics to improve safety assessment of therapeutics. Nat Rev Drug Discov. 2022; 22(2):145-162. DOI: 10.1038/s41573-022-00561-w. View

11.

Nguyen P, Born D, Deaton A, Nioi P, Ward L . Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects. Nat Commun. 2019; 10(1):1579. PMC: 6450952. DOI: 10.1038/s41467-019-09407-3. View

12.

Visscher P, Brown M, McCarthy M, Yang J . Five years of GWAS discovery. Am J Hum Genet. 2012; 90(1):7-24. PMC: 3257326. DOI: 10.1016/j.ajhg.2011.11.029. View

13.

King E, Davis J, Degner J . Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 2019; 15(12):e1008489. PMC: 6907751. DOI: 10.1371/journal.pgen.1008489. View

14.

Hingorani A, Kuan V, Finan C, Kruger F, Gaulton A, Chopade S . Improving the odds of drug development success through human genomics: modelling study. Sci Rep. 2019; 9(1):18911. PMC: 6906499. DOI: 10.1038/s41598-019-54849-w. View

15.

Reay W, Cairns M . Advancing the use of genome-wide association studies for drug repurposing. Nat Rev Genet. 2021; 22(10):658-671. DOI: 10.1038/s41576-021-00387-z. View

16.

Lommatzsch M, Brusselle G, Canonica G, Jackson D, Nair P, Buhl R . Disease-modifying anti-asthmatic drugs. Lancet. 2022; 399(10335):1664-1668. DOI: 10.1016/S0140-6736(22)00331-2. View

17.

Mortberg M, Vallabh S, Minikel E . Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials. Sci Rep. 2022; 12(1):17708. PMC: 9587287. DOI: 10.1038/s41598-022-21820-1. View

18.

Minikel E, Karczewski K, Martin H, Cummings B, Whiffin N, Rhodes D . Evaluating drug targets through human loss-of-function genetic variation. Nature. 2020; 581(7809):459-464. PMC: 7272226. DOI: 10.1038/s41586-020-2267-z. View

19.

Ference B, Ginsberg H, Graham I, Ray K, Packard C, Bruckert E . Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32):2459-2472. PMC: 5837225. DOI: 10.1093/eurheartj/ehx144. View

20.

Scannell J, Bosley J, Hickman J, Dawson G, Truebel H, Ferreira G . Predictive validity in drug discovery: what it is, why it matters and how to improve it. Nat Rev Drug Discov. 2022; 21(12):915-931. DOI: 10.1038/s41573-022-00552-x. View